A Phase 2 Open Label Pilot Study to Evaluate the Safety and Efficacy of Subcutaneously Administered ELX-02 in Patients with Alport Syndrome with Col4A5 and Col4A3/4 Nonsense Mutation

  • Kerr, Peter (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date5/12/224/12/27